Checkmate-141, 2016 trial summary

A randomised clinical trial investigating the effect of nivolumab versus standard treatment in 2L


NCT02105636    N Engl J Med 2016;375:1856-1867  

Studied treatment
Control treatment

Patients 2L
Group sizes-9 / -9

Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design

EndpointX1N1X0N0TE95% CI0,22,01,0

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-1867     [PMID: 27718784]   link to pdf   add to Mendeley record NCT02105636

Registering number NCT02105636 (see trial on
Code Name